Comparing bevacizumab and ranibizumab for initial reduction of central macular thickness in patients with retinal vein occlusions

Clinical Ophthalmology

Volumn 7, Issue , 2013, Pages 1377-1383

  Singer, Michael A ^a   Cohen, Steven R ^b   Groth, Sylvia L ^c   Porbandarwalla, Salman ^b  

^a Medical Center Ophthalmology   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Anti VEGF; Central macular thickness; Dexamethasone; Intravitreal implant; Macular edema; Retinal vein occlusion

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; RANIBIZUMAB;

AGED; ARTICLE; CENTRAL MACULAR THICKNESS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY DEVICE; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VISUAL ACUITY;

EID: 84880099506     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S46235     Document Type: Article

References (18)

1. Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion. The Beaver Dam eye study. Arch Ophthalmol. 2008;126:513-518.
2. US Census Bureau. Annual Estimates of the population by sex and fiveyear age groups for the United States: April 1, 2000 to July 1, 2007. NC-EST2007-01. Release Date: May 1, 2008. Available at: https://www.census.gov/prod/2008pubs/p70-117.pdf. Accessed February 16, 2010.
3. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117: 1102-1112.
4. [no authors listed]. Argon laser photocoagulation for macular edema in branch vein occlusion. Branch Vein Occlusion Study Group. Am J Ophthalmol. 1984;98:271-282.
5. [no authors listed]. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology. 1995;102:1425-1433.
6. Noma H, Funatsu H, Yamasaki M, et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol. 2005;140:256-261.
7. Noma H, Funatsu H, Mimura T, et al. Aqueous humor levels of vasoactive molecules correlate with vitreous levels and macular edema in central retinal vein occlusion. Eur J Ophthalmol. 2010;20:402-409.
8. Campochiaro PA, Hafiz G, Shah SM, et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther. 2008;16:791-799.
9. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117: 1124-1133.
10. Yilmaz T, Cordero-Coma M. Use of bevacizumab for macular edema secondary to branch retinal vein occlusion: a systematic review. Graefes Arch Clin Exp Ophthalmol. 2012;250:787-793.
11. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388-1398.
12. Labriola LT, Sadda SR. Rapid resolution of macular edema associated with central retinal vein occlusion using ranibizumab after failure with multiple bevacizumab injections. Semin Ophthalmol. 2011;26: 387-391.
13. Singer MA, Bell DJ, Woods P, et al. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion. Retina. 2012;32:1289-1294.
14. Pieramici DJ, Rabena MD. Anti-VEGF therapy: comparison of current and future agents. Eye (Lond). 2008;22:1330-1336.
15. Stewart MW, Rosenfeld PJ, Penha FM, et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor T{stroke}rap-eye). Retina. 2012;32:4344-4357.
16. Chan A, Duker JS, Ko TH, et al. Normal macular thickness measurements in healthy eyes using Stratus optical coherence tomography. Arch Ophthalmol. 2006;124:193-198.
17. Barnes Retina Institute. Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion (CRAVE). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011 [updated February 9, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01428388. Accessed May 20, 2013.
18. Singer MA, Bell DJ, Porbandarwalla S. Ischemia and VEGF in different retinal diseases and therapies: how does one influence the other? Retinal Physician. 2012;9:28-30.